Market Intelligence, Clinical Progress, and High-Purity Reagents for GPI-Anchored Protein Pathway Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PGAP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PGAP1 Recombinant Protein (Catalytic Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed for native fold. |
View PGAP1 Products |
| Gene Delivery | PGAP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional assays. |
View PGAP1 Products |
| Benchmark Ab | Anti-PGAP1 Recombinant Antibody Recombinant positive control for downstream validation. |
View PGAP1 Products |
| Validator | PGAP1 siRNA Set For target knockdown and specificity verification. |
View PGAP1 Products |
| Related Target A | PGAP2 Downstream GPI-anchor remodeling partner; crucial for membrane microdomain localization. |
View PGAP2 Products |
| Related Target B | PGAP3 GPI-anchor lipid remodeling acyltransferase; synergistic target in membrane protein sorting. |
View PGAP3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ER Membrane Protein Hydrophobicity & Folding | HEK293 expressed soluble catalytic domains with native glycosylation and >95% purity. |
| Subfamily Off-Target Cross-Screening | Homolog panel proteins (PGAP2, PGAP3) strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PGAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the GPI-anchor biosynthetic pathway is an emerging frontier in oncology, rare genetic disorders, and infectious diseases. PGAP1 (Post-GPI Attachment to Proteins 1) functions as a critical GPI inositol deacylase in the endoplasmic reticulum. Genetic deficiency in PGAP1 leads to severe intellectual disability (MRT42), making it a prime candidate for gene therapy and chaperone-based rescue strategies. In oncology, altering the GPI-anchor remodeling machinery disrupts the cell-surface expression of key signaling receptors and immune checkpoints, positioning PGAP1 as a novel target for combination immunotherapies.
"The race for PGAP1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule inhibitors and gene-delivery vectors. As first-generation therapies reach the clinic, the next wave of R&D is targeting specific ER-localization mechanisms and synergistic GPI-pathway modulation."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Oncology, Parasitic Infections | Enzymatic Activity Assay (Need High-Purity Soluble Catalytic Domain) |
| Gene Therapy / Lentivirus | Orphan Drug Developers | PGAP1-Deficiency (MRT42) | In vitro rescue validation (Need Lentivirus Premade Particles) |
| Monoclonal Antibodies | Translational Immunology Labs | Autoimmune Diseases | Surface Antigen Profiling (Need Sequence-Verified Benchmark Abs) |